Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Assenagon Asset Management cut its Ultragenyx stake by 94.6%, selling 2,136,807 shares and retaining 120,864 shares worth approximately $4.0 million. Institutional investors still own 97.67% of the company.
• Ultragenyx reported a better-than-expected quarter, with a loss of $0.90 per share versus the $1.22 consensus estimate and revenue of $214 million, up 28.5% year over year.
• Analysts remain broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $57.82 versus a recent price of $26.86, although longer-term 2027 earnings estimates were reduced.

Assenagon Asset Management S.A. lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 94.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 120,864 shares of the biopharmaceutical company's stock after selling 2,136,807 shares during the quarter. Assenagon Asset Management S.A. owned 0.12% of Ultragenyx Pharmaceutical worth $4,036,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Parallel Advisors LLC increased its stake in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,440 shares during the last quarter. Leonteq Securities AG lifted its stake in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,333 shares during the last quarter. Versant Capital Management Inc lifted its stake in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,001 shares during the last quarter. Danske Bank A S bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $39,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 1,845 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares of the company's stock, valued at $2,325,654.44. The trade was a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 14,292 shares of company stock worth $351,644. 5.20% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Stock Down 0.4%

Shares of Ultragenyx Pharmaceutical stock opened at $26.86 on Thursday. The firm has a market cap of $2.65 billion, a PE ratio of -4.60 and a beta of 0.35. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.29 and a 12-month high of $39.89. The company's fifty day simple moving average is $28.16 and its two-hundred day simple moving average is $24.90.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company's quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.17) earnings per share. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.08 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.75 from a loss of $0.84 per share and increased its Q4 2026 forecast to $0.78 from a loss of $0.35. The changes suggest expectations for a faster-than-anticipated improvement in Ultragenyx’s profitability. Ultragenyx Pharmaceutical Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $50 price target, well above the stock’s recent trading level. Separately, a brokerage consensus cited a price target of approximately $57.82, indicating substantial potential upside if the company executes on its pipeline and reaches profitability. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Neutral Sentiment: Ultragenyx and Baylor Research Institute reportedly settled a patent lawsuit involving generic competition to DOJOLVI. The settlement removes some litigation uncertainty, but the financial and commercial terms were not provided, limiting the immediate valuation impact. Ultragenyx and Baylor Settle DOJOLVI Patent Lawsuit
• Negative Sentiment: HC Wainwright lowered its 2027 EPS estimates across the board: Q1 to $0.06 from $0.27, Q2 to $0.91 from $1.18, Q3 to $1.25 from $1.54, Q4 to $2.27 from $2.63, and full-year 2027 to $4.50 from $5.61. These reductions weigh on longer-term earnings expectations, even though the analyst remains bullish.

Wall Street Analyst Weigh In

RARE has been the topic of a number of research reports. Barclays decreased their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating on the stock in a report on Wednesday, April 29th. Guggenheim cut their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating for the company in a research note on Tuesday, August 4th. Wells Fargo & Company reduced their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $57.82.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source